Argenta delivers preclinical candidate for Wellcome Trust funded, anti-aging project
The three-year project aimed at identifying selective inhibitors of the 11beta-HSD1 enzyme resulted in the identification of a lead candidate. The class of compounds, which will hopefully enter human clinical trials next year, is being investigated as a potential drug that could slow the natural decline in memory associated with aging. The preclinical candidate has been shown to improve cognitive and memory function in aging mice. The nomination of this preclinical candidate brings the total number of such candidates identified by Argenta in its 10 year history to over 35.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.